<DOC>
	<DOC>NCT02316613</DOC>
	<brief_summary>This French national, multicenter, prospective, longitudinal, observational study will describe the treatment modalities of a cohort of patients with relapsed or refractory follicular non-Hodgkin's lymphoma, with evaluation of the cohort overall and according to the presence or not of MabTheraÂ® (rituximab) maintenance therapy. Actively participating physicians will enroll patients and collect therapeutic management data in a real-life setting up to 5 years.</brief_summary>
	<brief_title>Prospective Observational Study on the Management of Patients With Relapsed or Refractory Follicular Lymphoma (OLYMPE)</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Follicular</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Adult patient (age &gt;/= 18 years) Presenting with WHO grade 13, CD20positive follicular nonHodgkin's lymphoma, histologically confirmed at initial diagnosis In relapse (or refractory) after at least one line of treatment, regardless of the nature of previous treatments (chemotherapy and/or immunotherapy and/or radioimmunoconjugate therapy and/or radiation+chemotherapy) and for whom a decision was made to give salvage therapy Having received oral and written information about the study and having raised no objections to electronic capture and processing of his/her personal data Patient participating in a clinical trial evaluating a new, noncommercialized cancer treatment at the time of inclusion Follicular lymphoma presenting with a transformation to diffuse large cell nonHodgkin's lymphoma First line treatment with radiotherapy alone Initial abstention from treatment (decision to not treat the progression at the time of inclusion in the OLYMPE study)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>